[
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "header",
    "content": "Protocol Summary",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Heading1",
      "entity": [],
      "roi_id": {
        "para": "4d9c70b7-20c2-40dc-94a8-84f876c5bc70",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "be7eb069-e494-4490-9000-0fb32978fbe6",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "4d8e62b9-0927-44d5-beda-4520cb15e70d",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Protocol Summary",
    "file_section_num": "1",
    "file_section_level": "1",
    "seq_num": 1,
    "qc_change_type": "",
    "line_id": "4d9c70b7-20c2-40dc-94a8-84f876c5bc70",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "header",
    "content": "Synopsis",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Heading2",
      "entity": [],
      "roi_id": {
        "para": "ee03b53a-4e3a-4daf-b4c0-98fde9d7a716",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "aec04015-c6e5-49af-ace2-f6a31b2e3ae1",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "d7e7b6ff-a108-4166-a38d-820f22bd83de",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 2,
    "qc_change_type": "",
    "line_id": "ee03b53a-4e3a-4daf-b4c0-98fde9d7a716",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "A Phase I, Open-label Study to Evaluate the Pharmacokinetics of Tezepelumab in Children ≥5 to 11 Years of Age with Mild, Moderate, or Severe Asthma. Protocol Title:",
    "font_info": {
      "IsBold": true,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "d9e5f8a9-a174-426b-b393-29fab0928bcb",
        "childbox": "",
        "subtext": ""
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "12902641-c7c4-40c2-b66f-b5e1f4e8300e",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "9e9d6a01-1681-4775-afe8-b08e1daaedab",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 3,
    "qc_change_type": "",
    "line_id": "d9e5f8a9-a174-426b-b393-29fab0928bcb",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "Short Title: A Study to Evaluate the Pharmacokinetics of Tezepelumab in Children ≥5to11Years of Age with Asthma.",
    "font_info": {
      "IsBold": true,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "44d665d8-3974-4e80-aba2-e6aec399a267",
        "childbox": "",
        "subtext": ""
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "1bc32c16-7a95-428b-8e25-44c6d7bdfcb7",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "c8c1e139-8533-4f1b-bcc5-7c617fa3feeb",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 4,
    "qc_change_type": "",
    "line_id": "44d665d8-3974-4e80-aba2-e6aec399a267",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ef9b1272-1c40-4c16-94ed-4121717ee904",
        "childbox": "",
        "subtext": ""
      }
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 5,
    "qc_change_type": "",
    "line_id": "ef9b1272-1c40-4c16-94ed-4121717ee904",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "The primary aim of this study is to evaluate the pharmacokinetic (PK) profile following a single subcutaneous (SC) 70 mg dose of tezepelumab in children aged ≥5 to 11years with mild, moderate, or severe asthma (Global Initiative for Asthma [GINA] 2019 Step 2 to Step 4) requiring daily controller medications.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "7693e085-8076-4c00-a470-c06557089963",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "bcee1bd4-30c1-42bd-b6c5-2b73f45226ae",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "8b19629b-74e2-478d-94eb-0d435db4920f",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 6,
    "qc_change_type": "",
    "line_id": "7693e085-8076-4c00-a470-c06557089963",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "Additional aims are to evaluate the safety, tolerability, immunogenicity and pharmacodynamics (PD) of a single SC 70 mg dose of tezepelumab.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "fecd69e0-5e4c-4a85-bf7b-651efab06042",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "540562a9-85b3-44c2-a2ad-fca910a81da6",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "c4a52b4f-d3cf-458a-aea6-62ea72ffafc5",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 7,
    "qc_change_type": "",
    "line_id": "fecd69e0-5e4c-4a85-bf7b-651efab06042",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "f8483642-f701-4dae-80cb-b4946d302b9d",
        "childbox": "",
        "subtext": ""
      }
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 8,
    "qc_change_type": "",
    "line_id": "f8483642-f701-4dae-80cb-b4946d302b9d",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "table",
    "content": {
      "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Objectives</td>\n      <td>Outcome Measures</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Primary</td>\n      <td>Primary</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>To describe the PK parameters following a single SC administration of tezepelumab 70 mg in children with mild, moderate, or severe asthma</td>\n      <td>Maximum concentration (C max ) Time to C max (t max ) Area under the concentration-time curve (AUC) Terminal phase elimination half-life (t 1/2 ) Apparent clearance (CL/F) Apparent steady-state volume of distribution (V ss /F)</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Secondary</td>\n      <td>Secondary</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>To evaluate the immunogenicity of tezepelumab</td>\n      <td>Presence of anti-drug antibodies (ADA)</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>Safety</td>\n      <td>Safety</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>To evaluate the safety and tolerability following a single SC administration of tezepelumab 70 mg</td>\n      <td>Adverse events/serious adverse events Vital signs Laboratory parameters Electrocardiogram (ECG)</td>\n    </tr>\n  </tbody>\n</table>",
      "TableProperties": "[{\"1.0\":{\"entities\":[],\"content\":\"Objectives\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"2a711983-8654-48e9-8a0a-08534dfba64d\",\"column_roi_id\":\"3d45aa65-422b-4c9a-889d-67df282fdfc0\",\"datacell_roi_id\":\"5c600f6b-b9e8-4b6c-ad58-c20d0cdcaf6f\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Outcome Measures\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"2a711983-8654-48e9-8a0a-08534dfba64d\",\"column_roi_id\":\"73afc772-a90c-49ee-bf66-4f3f12a580ed\",\"datacell_roi_id\":\"12d6451c-a171-477d-a3fe-05cffd47005b\"},\"table_index\":2.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Primary\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"8bf2406f-c3a6-4f28-89b5-81a99b08dd0f\",\"column_roi_id\":\"52a18286-bfba-4393-b380-ef0fade7a93b\",\"datacell_roi_id\":\"5316a397-0d62-4211-b29f-c37380f8d4bc\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Primary\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"8bf2406f-c3a6-4f28-89b5-81a99b08dd0f\",\"column_roi_id\":\"52a18286-bfba-4393-b380-ef0fade7a93b\",\"datacell_roi_id\":\"5316a397-0d62-4211-b29f-c37380f8d4bc\"},\"table_index\":2.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"To describe the PK parameters following a single SC administration of tezepelumab 70\\u00a0mg in children with mild, moderate, or severe asthma\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"0a173394-f7eb-48f1-a121-526605f484f1\",\"column_roi_id\":\"066cffe7-79dd-4803-a9e6-b84f68e53e57\",\"datacell_roi_id\":\"0bb3fce6-37f7-4432-996c-4e9f726dfc66\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Maximum concentration (C max ) Time to C max (t max ) Area under the concentration-time curve (AUC) Terminal phase elimination half-life (t 1\\/2 ) Apparent clearance (CL\\/F) Apparent steady-state volume of distribution (V ss \\/F)\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"0a173394-f7eb-48f1-a121-526605f484f1\",\"column_roi_id\":\"540aa63e-1f21-4a5d-aef3-55edcfb1ca2d\",\"datacell_roi_id\":\"bc7b1917-e3e0-4a48-aa1b-4a9de08ec8fb\"},\"table_index\":2.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Secondary\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"c2011a1d-c7d8-428b-b56f-f0647d19347e\",\"column_roi_id\":\"eef4c916-cc87-4bf2-b73e-cfa54fe9effa\",\"datacell_roi_id\":\"34da9a99-e00c-4d34-9d53-0acffa10f1d1\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Secondary\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"c2011a1d-c7d8-428b-b56f-f0647d19347e\",\"column_roi_id\":\"eef4c916-cc87-4bf2-b73e-cfa54fe9effa\",\"datacell_roi_id\":\"34da9a99-e00c-4d34-9d53-0acffa10f1d1\"},\"table_index\":2.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"To evaluate the immunogenicity of tezepelumab\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"63456b2c-ff5b-4bee-8a31-1d627f54830b\",\"column_roi_id\":\"1ce3817c-46a1-44a3-bb5d-0e8fe33d11ee\",\"datacell_roi_id\":\"a4489138-7392-41f4-a9bd-5fa2ef945963\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Presence of anti-drug antibodies (ADA)\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"63456b2c-ff5b-4bee-8a31-1d627f54830b\",\"column_roi_id\":\"e76b2e20-9715-443b-b39d-3284445c9853\",\"datacell_roi_id\":\"312ca159-ec01-4eaf-a4be-664e3af2a453\"},\"table_index\":2.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Safety\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"626f1df8-e52a-4637-a696-d27303c9e6da\",\"column_roi_id\":\"b9019d30-90c4-49db-8096-6cc1ed7b04e9\",\"datacell_roi_id\":\"286d21a0-b18c-492f-b73e-52b27061d4d1\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Safety\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"626f1df8-e52a-4637-a696-d27303c9e6da\",\"column_roi_id\":\"b9019d30-90c4-49db-8096-6cc1ed7b04e9\",\"datacell_roi_id\":\"286d21a0-b18c-492f-b73e-52b27061d4d1\"},\"table_index\":2.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"To evaluate the safety and tolerability following a single SC administration of tezepelumab 70\\u00a0mg\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"95cbad49-6305-4153-9c5e-84138eb13065\",\"column_roi_id\":\"3964ea96-947d-4a51-a750-dceea7170ec9\",\"datacell_roi_id\":\"f12bcbf2-b220-4f2f-aac3-ecbfcb930e7d\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Adverse events\\/serious adverse events Vital signs Laboratory parameters Electrocardiogram (ECG)\",\"roi_id\":{\"table_roi_id\":\"1e18fc98-f444-48a1-96b9-661f7ac0dcb7\",\"row_roi_id\":\"95cbad49-6305-4153-9c5e-84138eb13065\",\"column_roi_id\":\"e5673f02-3d19-4cc6-aeb5-8445af29aec3\",\"datacell_roi_id\":\"2c3f3844-9f6b-4bef-be7e-b69e334c54af\"},\"table_index\":2.0,\"qc_change_type\":\"\"}}]",
      "TableName": "1.1 Synopsis",
      "TableIndex": "3",
      "Header": []
    },
    "font_info": {
      "IsBold": false,
      "font_size": 24,
      "font_style": "TableHead",
      "entity": [],
      "roi_id": {
        "para": "5c600f6b-b9e8-4b6c-ad58-c20d0cdcaf6f",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "a8aa58ca-ba28-42e8-9d30-1728cfede632",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "97366d46-9bc6-4de7-950e-701c3671db78",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": 24,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 9,
    "qc_change_type": "",
    "line_id": "5c600f6b-b9e8-4b6c-ad58-c20d0cdcaf6f",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "PK Pharmacokinetic; SC Subcutaneous.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "TableFootnoteInfo",
      "entity": [],
      "roi_id": {
        "para": "83525067-2adb-4991-ba0c-81e86dc09f58",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "aa0c179b-b183-493b-a1a8-8337ff1713ef",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "209dcc28-6d25-4a57-a155-914078dd40ac",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 10,
    "qc_change_type": "",
    "line_id": "83525067-2adb-4991-ba0c-81e86dc09f58",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "TableFootnoteInfo",
      "entity": [],
      "roi_id": {
        "para": "c1ade3da-9d50-4672-93ab-f3dd0f050889",
        "childbox": "",
        "subtext": ""
      }
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 11,
    "qc_change_type": "",
    "line_id": "c1ade3da-9d50-4672-93ab-f3dd0f050889",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "For the exploratory objective (PD) and outcome measures, see Section of the protocol. 3",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "1c736500-b31a-4bdc-802b-f05b6d56d63a",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "18bde816-f217-4948-b6af-aa29027fbd7c",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "3f2e8262-b2c7-4f9c-ad4c-cd31c7ff5f5a",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 12,
    "qc_change_type": "",
    "line_id": "1c736500-b31a-4bdc-802b-f05b6d56d63a",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "e287536e-a050-438d-9dea-63065932a1a2",
        "childbox": "",
        "subtext": ""
      }
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 13,
    "qc_change_type": "",
    "line_id": "e287536e-a050-438d-9dea-63065932a1a2",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "This is a multicentre, open-label study designed to evaluate the PK profile of tezepelumab following a single SC 70mg dose in children ≥5to11years of age with mild, moderate, or severe asthma.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "9a087510-5a04-4aa9-8ea6-a7ac4a4c4e16",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "4ea3faa7-eabd-490b-a73a-85001321482d",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "088e635e-f061-4f46-8aef-46d3704ca65c",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 14,
    "qc_change_type": "",
    "line_id": "9a087510-5a04-4aa9-8ea6-a7ac4a4c4e16",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "The study will be conducted in 3to5 sites in the United Kingdom.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "81f3da47-5289-4c95-be94-8896db0e65bb",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "8e282873-9894-46c1-a57c-2686be6f4ae4",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "cd223729-8958-44db-88a2-658c5589854d",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 15,
    "qc_change_type": "",
    "line_id": "81f3da47-5289-4c95-be94-8896db0e65bb",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "At least 12 paediatric subjects aged ≥5to11years (inclusive) will receive a single SC 70 mg dose of tezepelumab. Approximately 24 subjects will be enrolled such that at least 12subjects complete the study. At least 4subjects will have body weight <25kg and a minimum of 3subjects will have body weight ≥25kgto<40kg.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "5d255ae9-9c41-488d-a56f-b5fd8e0abdfc",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "cacd2434-af29-411b-97d8-25ffe225eb98",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "aac8ffc5-fd8b-4409-860c-a50e5685cb32",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 16,
    "qc_change_type": "",
    "line_id": "5d255ae9-9c41-488d-a56f-b5fd8e0abdfc",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "The 99-day study consists of:",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "8e93c8d9-3fa9-4f7f-9c54-f113d67c1012",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "4fad8b75-325b-42e4-ab41-c5d59ccf2fc4",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "ec36f43a-f366-4c78-bd66-f07276b5f42c",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 17,
    "qc_change_type": "",
    "line_id": "8e93c8d9-3fa9-4f7f-9c54-f113d67c1012",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "A consent/screening period of up to 14days",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "ListBullet",
      "entity": [],
      "roi_id": {
        "para": "90cb7538-43c6-487a-895c-768dd446af7f",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "cbb1cfbd-af2c-410b-a86e-52a76ca6e7ad",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "35eae447-64e5-48be-8b6e-d23e2b03bde7",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 18,
    "qc_change_type": "",
    "line_id": "90cb7538-43c6-487a-895c-768dd446af7f",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "Treatment and follow-up period of 85days.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "ListBullet",
      "entity": [],
      "roi_id": {
        "para": "82593649-4f87-4fb5-9e7e-34563fdc0ae9",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "b87e064f-dd88-42c3-9147-ba182c18d955",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "c20ce66d-7e92-41a0-a624-9cb3e614ddd7",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 19,
    "qc_change_type": "",
    "line_id": "82593649-4f87-4fb5-9e7e-34563fdc0ae9",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "ListEnd",
      "entity": [],
      "roi_id": {
        "para": "59587436-e798-4a16-b607-83d93905d418",
        "childbox": "",
        "subtext": ""
      }
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 20,
    "qc_change_type": "",
    "line_id": "59587436-e798-4a16-b607-83d93905d418",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "This is an open-label non-randomised study. Subjects will be allocated to receive tezepelumab if they fulfil the eligibility criteria.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "1e74b76a-9a0c-43e1-a8fe-9e22bc804254",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "b7407a58-05fb-4754-a38d-3f4e85e7ec7d",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "aa754563-eda9-48da-88e8-a4948e03ff11",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 21,
    "qc_change_type": "",
    "line_id": "1e74b76a-9a0c-43e1-a8fe-9e22bc804254",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "Disclosure Statement : This is an open-label single arm study.",
    "font_info": {
      "IsBold": true,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "60d45379-701e-4858-bb2a-9dad0691ef51",
        "childbox": "",
        "subtext": ""
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "4dda5438-8e0a-4d87-9c8c-d7e0c405a96b",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "b132bebd-02a9-41b2-b3a8-376331e0fe4e",
      "rFonts": "Times New Roman Bold",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 22,
    "qc_change_type": "",
    "line_id": "60d45379-701e-4858-bb2a-9dad0691ef51",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "e9c1112b-1390-4853-930c-bff41f988ac7",
        "childbox": "",
        "subtext": ""
      }
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 23,
    "qc_change_type": "",
    "line_id": "e9c1112b-1390-4853-930c-bff41f988ac7",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "Approximately 24 subjects will be enrolled such that at least 12subjects complete the study.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "ad0c2a58-1759-4c13-b5fe-85e7c5a2b56e",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "7f187449-bffd-4b20-977a-b62f7e0977e1",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "8a71875d-198e-45b9-a784-cce4629028a1",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 24,
    "qc_change_type": "",
    "line_id": "ad0c2a58-1759-4c13-b5fe-85e7c5a2b56e",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "Potential subjects who are screened for the purpose of determining eligibility for the study but are not assigned in the study, are considered ‘screen failures’, unless otherwise specified by the protocol. Note : ‘Enrolled’ means a subject’s, and their legally acceptable representative’s agreement to participate in a clinical study following completion of the informed consent process.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "7f7c6984-c9f6-48d2-86b7-41cfae2a8d9a",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "4c03bf0c-415a-42c3-a6dd-61032569bee3",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "efd63ece-1f20-46c2-acfe-cac1fadfd56a",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 25,
    "qc_change_type": "",
    "line_id": "7f7c6984-c9f6-48d2-86b7-41cfae2a8d9a",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "05f16c76-9964-4bb5-bb1f-d4335dc6212c",
        "childbox": "",
        "subtext": ""
      }
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 26,
    "qc_change_type": "",
    "line_id": "05f16c76-9964-4bb5-bb1f-d4335dc6212c",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "This is a 99-day study. The study will be completed after the EOS visit on Day85. Subjects who meet eligibility criteria will receive a single SC 70 mg dose of tezepelumab on Day1. Screening assessments should be completed within 14days (Day-14 to Day-1). The subjects will then return for Follow-up visits on Days 3, 7, 11, 15, 29, 57 and 85 (End of Study [EOS]).",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "ce0ce39e-f31c-4b99-b1f3-49903c5fc2c8",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "313450b5-7ad3-4ae7-90f3-ab623aec65d8",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "cb90e69c-1bb1-4c24-8927-530b24c58b3f",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 27,
    "qc_change_type": "",
    "line_id": "ce0ce39e-f31c-4b99-b1f3-49903c5fc2c8",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "2ce8c4a1-3e11-4b60-840a-46d564ada1e0",
        "childbox": "",
        "subtext": ""
      }
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 28,
    "qc_change_type": "",
    "line_id": "2ce8c4a1-3e11-4b60-840a-46d564ada1e0",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "48007838-39e8-4647-bb1a-28d892ab19da",
        "childbox": "",
        "subtext": ""
      }
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 29,
    "qc_change_type": "",
    "line_id": "48007838-39e8-4647-bb1a-28d892ab19da",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "All data will be presented using descriptive statistics. No formal statistical hypothesis tests will be made.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "642ea677-a4c7-45a4-a111-5813349fc361",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "878d8702-5dac-4145-9a75-f2a4e9023d71",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "fb10a046-ad16-4498-aa26-53d9776e0b9c",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 30,
    "qc_change_type": "",
    "line_id": "642ea677-a4c7-45a4-a111-5813349fc361",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "Additional PK parameters may be reported if appropriate. max maximum concentration (C max AUC 0-inf The following PK parameters will be estimated by noncompartmental analysis: area under the concentration-time curve (AUC) 0-last (t max ), terminal half-life (t 1/2 ), apparent clearance (CL/F) and apparent steady-state volume of distribution (V ss /F). ), time to C Individual tezepelumab serum concentration data will be tabulated along with descriptive statistics.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "e7df71b1-aad7-4e2d-b83f-959d5636c8f7",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "cdf1e4f8-02ab-4e79-8ef0-bbad2f1fe16b",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "24e3fdee-c4fc-4bd3-9cd7-9b045b676f9a",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 31,
    "qc_change_type": "",
    "line_id": "e7df71b1-aad7-4e2d-b83f-959d5636c8f7",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "Other variables used for the safety assessments include but are not limited to electrocardiograms (ECGs), vital signs and routine laboratory assessments. Safety will be assessed by summarising adverse events (AEs) and serious AEs (SAEs). These variables as well as their changes from baseline will be summarised descriptively.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "860bf2a3-e29d-4bfd-95a8-d1193ef85355",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "18b04141-8b79-408c-aa9b-d52090109c3a",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "e6164d92-061c-4f21-9faa-8b5d711828fa",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 32,
    "qc_change_type": "",
    "line_id": "860bf2a3-e29d-4bfd-95a8-d1193ef85355",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "The incidence of positive serum antibodies to tezepelumab will be reported.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "eab991c4-5ae6-4903-b9d5-0f226048d33d",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "2091d03e-fa4a-41a7-9609-ce3ce696c30d",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "b84d0a9f-5183-4f91-9029-ccba87c5b2e8",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 33,
    "qc_change_type": "",
    "line_id": "eab991c4-5ae6-4903-b9d5-0f226048d33d",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "Anti-drug antibodies (ADA) and PD parameter summaries and safety presentations will be based on the safety analysis set. All PK summaries will be based on the PK analysis set.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "af8d0ba8-1b70-48a4-a9cb-03970304f685",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "8eb55380-77f0-4142-a1b4-30ee30422aa3",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "0eb7ea3a-4f2a-4e41-a950-3e0d08c7f01c",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 34,
    "qc_change_type": "",
    "line_id": "af8d0ba8-1b70-48a4-a9cb-03970304f685",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "No formal sample size calculation was conducted for this study. A total of 12subjects treated with tezepelumab is considered sufficient to provide adequate data to characterise PK of tezepelumab in children ≥5 to 11 years of age. The number of subjects was based on the desire to obtain adequate PK and safety data while exposing as few paediatric subjects as possible to tezepelumab and study procedures.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "ee8d5c46-a6c2-4e11-8893-c78df2a8c138",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "e3dee99a-eb45-4a86-8e75-bbde34f2b5b1",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "9a618443-d3a8-4c49-9a61-de1aa82786c0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "5dc494e6-9724-42c0-a362-e4a655651919",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Synopsis",
    "file_section_num": "1.1",
    "file_section_level": "2",
    "seq_num": 35,
    "qc_change_type": "",
    "line_id": "ee8d5c46-a6c2-4e11-8893-c78df2a8c138",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "header",
    "content": "Schema",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Heading2",
      "entity": [],
      "roi_id": {
        "para": "55fe84e0-df2a-4b62-8489-6ca8a4990cea",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "a6f0549b-9b25-43c4-b948-26997a8ad1e5",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "52c9c25f-cc01-44e6-882a-29ba8934f3d0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "c6dd4ee0-1501-4bd0-aa8e-6ae48e3f1137",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Schema",
    "file_section_num": "1.2",
    "file_section_level": "2",
    "seq_num": 36,
    "qc_change_type": "",
    "line_id": "55fe84e0-df2a-4b62-8489-6ca8a4990cea",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "Figure 1 The study design is shown in .",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Paragraph",
      "entity": [],
      "roi_id": {
        "para": "2f8f0ab1-ee84-4b49-8296-9991505dd481",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "Highlight": "",
      "id": "8cbded31-5aad-4068-9126-0aed7fb09d8d",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "53e2a71b-4385-4393-a91e-d187cea44500",
      "link_id_level2": "52c9c25f-cc01-44e6-882a-29ba8934f3d0",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "dac87bd9-4ac6-4d19-9cc3-f8bdfd3709e5",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "Schema",
    "file_section_num": "1.2",
    "file_section_level": "2",
    "seq_num": 37,
    "qc_change_type": "",
    "line_id": "2f8f0ab1-ee84-4b49-8296-9991505dd481",
    "aidocid": "74646d51-2f7b-4a8b-a86f-8da709ea4e5c",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "audit": {
      "last_updated_user": "1072234",
      "updated_time": "2022-05-12T08:53:42.883000"
    }
  }
]